📰 Nasdaq Huma News
Page 3 - Nasdaq Huma News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Huma. Real-time updates on events, politics, business and more.
August 18, 2023
Piper Sandler upgraded shares of Humacyte (NASDAQ:HUMA – Free Report) from an underweight rating to a neutral rating in a research note issued to investors on Monday, Marketbeat reports. The brokerage currently has $3.50 price objective on the stock, up from their previous price objective of $2.75. Separately, Cantor Fitzgerald initiated coverage on Humacyte in […]
August 5, 2023
Humacyte (NASDAQ:HUMA – Get Free Report) and Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation. Profitability This table compares Humacyte and Kymera Therapeutics’ […]
June 25, 2023
Cantor Fitzgerald started coverage on shares of Humacyte (NASDAQ:HUMA – Get Rating) in a report published on Thursday, The Fly reports. The brokerage issued an overweight rating and a $6.00 target price on the stock. Separately, Benchmark reissued a buy rating and issued a $16.00 price objective on shares of Humacyte in a research report […]
June 19, 2023
Humacyte, Inc. (NASDAQ:HUMA – Get Rating) CEO Laura E. Niklason sold 500,000 shares of the business’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $3.12, for a total transaction of $1,560,000.00. Following the transaction, the chief executive officer now directly owns 9,990,736 shares in the company, […]
May 31, 2023
Humacyte, Inc. (NASDAQ:HUMA – Get Rating) saw a significant increase in short interest during the month of May. As of May 15th, there was short interest totalling 5,520,000 shares, an increase of 5.7% from the April 30th total of 5,220,000 shares. Based on an average daily volume of 262,600 shares, the days-to-cover ratio is presently […]
May 29, 2023
Humacyte, Inc. (NASDAQ:HUMA – Get Rating) CEO Laura E. Niklason sold 2,625,000 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $2.75, for a total transaction of $7,218,750.00. Following the completion of the sale, the chief executive officer now directly owns […]
November 10, 2022
-- Progress Continues in Clinical Development of Human Acellular Vessel™ (HAV™) for Vascular Trauma; BLA Filing Anticipated mid 2023 – -- Experience with...
August 15, 2022
-- Human Acellular Vessels™ (HAVs™) successfully implanted in wounded Ukrainian citizens and reported to be functioning, saving limbs – -- Hosted key...
July 7, 2022
Thursday, July 14, 2022 @ 11:30 a.m. ET...
June 27, 2022
Industry leader brings deep expertise in international drug development, strategic leadership, and corporate partnering for biopharmaceutical companies...